1. Wang, Huanbin, Yao, Han, Li, Chushu, Fang, Jing-Yuan, Xu, Jie. 2018. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. In Nature chemical biology, 15, 42-50. doi:10.1038/s41589-018-0161-x. https://pubmed.ncbi.nlm.nih.gov/30397328/
2. Koh, Young Wha, Han, Jae-Ho, Haam, Seokjin, Lee, Hyun Woo. 2020. HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis. In Journal of clinical medicine, 9, . doi:10.3390/jcm9051425. https://pubmed.ncbi.nlm.nih.gov/32403421/
3. Zhu, Sixian, Xu, Huiting, Chen, Runzhi, Tong, Jin, Fu, Qiang. 2023. DNA methylation and miR-92a-3p-mediated repression of HIP1R promotes pancreatic cancer progression by activating the PI3K/AKT pathway. In Journal of cellular and molecular medicine, 27, 788-802. doi:10.1111/jcmm.17612. https://pubmed.ncbi.nlm.nih.gov/36811277/
4. Zhu, Jinliang, Wang, Xin, Guan, Huiyuan, Song, Yongxi, Wang, Zhenning. 2020. HIP1R acts as a tumor suppressor in gastric cancer by promoting cancer cell apoptosis and inhibiting migration and invasion through modulating Akt. In Journal of clinical laboratory analysis, 34, e23425. doi:10.1002/jcla.23425. https://pubmed.ncbi.nlm.nih.gov/32548851/
5. Yang, Nengli, Liang, Yafeng, Yang, Pei, Jiang, Liuming. 2022. Flurbiprofen inhibits cell proliferation in thyroid cancer through interrupting HIP1R-induced endocytosis of PTEN. In European journal of medical research, 27, 29. doi:10.1186/s40001-022-00658-3. https://pubmed.ncbi.nlm.nih.gov/35209947/
6. Wong, K K, Gascoyne, D M, Brown, P J, Green, T M, Banham, A H. 2013. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. In Leukemia, 28, 362-72. doi:10.1038/leu.2013.224. https://pubmed.ncbi.nlm.nih.gov/23884370/
智鼠故事 
